Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Imaging Profile After Treatment with Tocilizumab in COVID-19: A Case Series

Author(s): Donato Lacedonia, Pasquale Tondo*, Giulia Scioscia, Paolo Fuso, Cosimo C. De Pace, Ennio V. Sassani and Maria Pia Foschino Barbaro

Volume 19, Issue 8, 2023

Published on: 23 September, 2022

Article ID: e190822207716 Pages: 6

DOI: 10.2174/1573405618666220819121114

Price: $65

Abstract

Introduction: COVID-19 is a pandemic disease, mainly affecting the respiratory tract, triggering an inflammatory cascade complicated by multiorgan failure up to death. Among the tested medications for this disease, tocilizumab appears to act directly on the inflammatory cascade, improving COVID-19 outcomes. For this reason, we have tested the efficacy of tocilizumab on lung damage using chest computed tomography (CT).

CASE Presentation: The study was conducted on twenty-one hospitalised COVID-19 patients between March-June 2020. Patients were divided into 2 groups according to the therapies administered (TCZ group= treatment with tocilizumab and NTZ group= other therapies). At admission, TCZ group presented worse laboratory test values, respiratory profile (PaO2/FiO2 ratio: 145.37±38.16 mmHg vs 257.9±95.3 mmHg of NTZ group, P<0.01) and radiological signs (multifocal opacity at chest-X-ray: 88% vs 23% of NTZ group, P<0.01). After performing chest CT during the clinical recovery, the scans of the 2 groups were compared and we observed that some features (e.g., ground glass opacity, consolidation and parenchymal bands) were less marked in the TCZ group.

Conclusion: In our study, patients treated with tocilizumab presented a worse overall clinical and radiological profile at admission, but the control CT showed a similar imaging profile to patients treated with standard therapy. Based on this evidence, we may suggest that tocilizumab plays an important role in COVID-19 patients in reducing lung inflammation.

Keywords: Computed tomography, COVID-19, lung involvement, SARS-CoV-2, Tocilizumab, therapy.

Graphical Abstract

[1]
WHO/Europe | Coronavirus disease (COVID-19) outbreak - WHO announces COVID-19 outbreak a pandemic. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic (Accessed on May 11, 2020).
[2]
Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. J Med Virol 2020; 92(9): 1401-3.
[http://dx.doi.org/10.1002/jmv.25990] [PMID: 32383171]
[3]
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020; 50(4): 332-4.
[http://dx.doi.org/10.1016/j.medmal.2020.03.007] [PMID: 32243911]
[4]
Chen J, Li K, Zhang Z, Li K, Yu PS. A survey on applications of artificial intelligence in fighting against COVID-19. ACM Comput Surv 2021; 54(8): 1-32.
[http://dx.doi.org/10.1145/3465398]
[5]
Böger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control 2021; 49(1): 21-9.
[http://dx.doi.org/10.1016/j.ajic.2020.07.011] [PMID: 32659413]
[6]
Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020; 296(2): E32-40.
[http://dx.doi.org/10.1148/radiol.2020200642] [PMID: 32101510]
[7]
Scioscia G, Mirabella L, Tondo P, et al. Impact of CT scan phenotypes in clinical manifestations, management and outcomes of hospitalised patients with COVID-19. Arch Bronconeumol 2022; 58: 63-5.
[http://dx.doi.org/10.1016/j.arbres.2021.07.008] [PMID: 34334880]
[8]
Li Y, Xia L. Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management. AJR Am J Roentgenol 2020; 214(6): 1280-6.
[http://dx.doi.org/10.2214/AJR.20.22954] [PMID: 32130038]
[9]
Belen-Apak FB, Sarialioglu F. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses 2020; 142: 109743.
[http://dx.doi.org/10.1016/j.mehy.2020.109743] [PMID: 32335456]
[10]
Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020; 92(10): 2042-9.
[http://dx.doi.org/10.1002/jmv.25964] [PMID: 32369191]
[11]
Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med 2020; 58(7): 1095-9.
[http://dx.doi.org/10.1515/cclm-2020-0398] [PMID: 32301746]
[12]
Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med 2020; 18(1): 405.
[http://dx.doi.org/10.1186/s12967-020-02573-9] [PMID: 33087150]
[13]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 323(18): 1824-36.
[http://dx.doi.org/10.1001/jama.2020.6019] [PMID: 32282022]
[14]
Drugs that can be used for the treatment of COVID19 disease | Italian Medicines Agency. Available from: https://www.aifa.gov.it/aggiorna-mento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19 (Accessed on May 14, 2020).
[15]
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020; 215(1): 87-93.
[http://dx.doi.org/10.2214/AJR.20.23034] [PMID: 32174129]
[16]
Ng MY, Lee EYP, Yang J, et al. Imaging profile of the COVID-19 infection: Radiologic findings and literature review. Radiol Cardiothorac Imaging 2020; 2(1): e200034.
[http://dx.doi.org/10.1148/ryct.2020200034] [PMID: 33778547]
[17]
Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: Glossary of terms for thoracic imaging. Radiology 2008; 246(3): 697-722.
[http://dx.doi.org/10.1148/radiol.2462070712] [PMID: 18195376]
[18]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117(20): 10970-5.
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[19]
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol 2020; 92(11): 2283-5.
[http://dx.doi.org/10.1002/jmv.25948] [PMID: 32343429]
[20]
Amiral J, Vissac AM, Seghatchian J. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? Transfus Apheresis Sci 2020; 59(3): 102804.
[http://dx.doi.org/10.1016/j.transci.2020.102804] [PMID: 32387238]
[21]
Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R. Cytokine storm syndrome in severe COVID-19. Autoimmun Rev 2020; 19(7): 102562.
[http://dx.doi.org/10.1016/j.autrev.2020.102562] [PMID: 32376400]
[22]
Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020; 50(5): 397-400.
[http://dx.doi.org/10.1016/j.medmal.2020.05.001] [PMID: 32387320]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy